Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 105Carcinoma, Renal Cell 38Leukemia, Myeloid, Acute 36Neoplasm Metastasis 31Neoplasms 22Breast Neoplasms 22Lymphoma, Non-Hodgkin 21Kidney Neoplasms 20Leukemia 18Carcinoma, Non-Small-Cell Lung 18Skin Neoplasms 17Neuroblastoma 17Ovarian Neoplasms 16Colorectal Neoplasms 16Recurrence 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 13Myelodysplastic Syndromes 10Uveal Melanoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Multiple Myeloma 8Congenital Abnormalities 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lung Neoplasms 7Hodgkin Disease 7Squamous Cell Carcinoma of Head and Neck 6

Interventions

Cyclophosphamide 18ofatumumab 14fludarabine 12Rituximab 11ibrutinib 10fludarabine phosphate 9acalabrutinib 7obinutuzumab 6Lenalidomide 6Bendamustine Hydrochloride 6venetoclax 5pirtobrutinib 4Vincristine 4Mesna 4Melphalan 4Immunotherapy, Adoptive 4Whole-Body Irradiation 3Mycophenolic Acid 3Chlorambucil 3Bortezomib 3Alemtuzumab 3spebrutinib 2navitoclax 2idelalisib 2Tacrolimus 2Tablets 2Stem Cell Transplantation 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2KW-2478 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, B-Cell × Interleukin-2 × Clear all
NCT03098355 2024-03-18

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Zhujiang Hospital

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡